Presspart is a specialty manufacturer of a multitude of metal and plastic products for the pharmaceutical industry. These products include highly complex, special-purpose components for which the highest precision and quality are absolutely crucial.

 

Innovation is the result of continuous development. Turning raw material into a finished product that is precision manufactured down to the last micron requires complex and highly sophisticated processes. At Presspart, these processes are constantly studied, refined and optimized. This approach enables the company to offer new solutions to customers, such as manufacturing deep-drawn components which were previously produced by other methods.

  

Presspart's expertise also allows components to be manufactured from a wide range of materials, many of them difficult to form using other processes. The acquisition of the Nemo Company in 2008 gave Presspart the opportunity to develop its product offerings into the area of plastic parts and assembled devices.

  

Because many of Presspart's products are used in the pharmaceutical industry, top priority is given to precision and quality. Three quarters of all metered dose inhalers used around the world incorporate components from Presspart. The company bears an enormous responsibility, as these products are used by millions of patients with asthma and other chronic respiratory diseases. 

 

Respiratory diseases of this kind will, according to forecasts published by the WHO, increase dramatically over the next decades.

 

One of Presspart's recent innovations has been to develop a special anodized aluminum can and stainless steel metering valve stem for use in a new inhalation device for insulin. This device will reduce the need for injections and could revolutionize the lives of many diabetics.

 

Advanced production methods are not the only important criteria - the quality must also be "right the first time". Cleanroom production environments ensure the lowest possible risk of contamination of these critical components. Regular in-process monitoring, automated end-of-line 100% inspection systems and analytical laboratory facilities render subsequent quality testing by customers superfluous.